Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06230666

Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases

Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases: a Randomized Controlled Non-inferiority Clinical Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
62 (estimated)
Sponsor
Matthias Guckenberger · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this randomized non-inferiority clinical trial is to investigate whether single-isocenter SBRT using one treatment plan is similarly effective as multiple-isocenter SBRT using multiple treatment plans for multiple extracranial metastases. The main question it aims to answer is: \- whether 1-year freedom from local disease progression at the site of treated metastases after single-isocenter SBRT is non-inferior against multiple-isocenter SBRT at the same prescription doses. Cancer patients with multiple extracranial distant metastases will be randomly assigned and treated either with single-isocenter SBRT or multiple-isocenter SBRT.

Detailed description

Treatment planning of SBRT for multiple metastases usually employs multiple isocenters, one for each target, resulting in multiple treatment plans. Execution of such treatments requires sequential multiple setups and treatment plan verifications. This practice complicates the workflow of SBRT planning and delivery and makes target-by-target treatment lengthy and patient compliance and comfort suboptimal. The investigators hypothesized that single-isocenter SBRT for extracranial multiple metastases is non-inferior in terms of local efficacy as compared to multiple-isocenter SBRT at the same radiation dose prescription.

Conditions

Interventions

TypeNameDescription
RADIATIONSBRTStereotactic Body Radiation Therapy

Timeline

Start date
2024-02-19
Primary completion
2026-12-30
Completion
2027-12-30
First posted
2024-01-30
Last updated
2024-03-13

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT06230666. Inclusion in this directory is not an endorsement.